ecrin-mdr-crcClinical2007Breast CarcinomaCarcinomaAnal CarcinomaBiliary Tract NeoplasmsCervical CarcinomaMesotheliomaTesticular CancerLiver CancerEndometrial NeoplasmsBreast NeoplasmsPancreatic CarcinomaSoft Tissue SarcomasEsophageal NeoplasmsRenalCarcinoma of Unknown Origin, PrimaryGastric CancerPancreatic NeoplasmsColorectalBone SarcomasSarcomaMelanomaSmall Cell Lung CarcinomaOvarianGallbladder CancerEsophageal CarcinomaCarcinoma, NeuroendocrineBiliary Tract CancerThyroid CancerNeuroendocrine CancerGallbladder NeoplasmsProstateTesticular NeoplasmsEndometrial CarcinomaBreast CarcinomaCarcinomaAnal CarcinomaBiliary Tract NeoplasmsCervical CarcinomaMesotheliomaLiver CancerTesticular CancerEndometrial NeoplasmsBreast NeoplasmsPancreatic CarcinomaSoft Tissue SarcomasEsophageal NeoplasmsRenalGastric CancerPancreatic NeoplasmsCarcinoma Of Unknown Origin, PrimaryBone SarcomasColorectalSarcomaMelanomaSmall Cell Lung CarcinomaOvarianGallbladder CancerEsophageal CarcinomaCarcinoma, NeuroendocrineBiliary Tract CancerThyroid CancerNeuroendocrine CancerGallbladder NeoplasmsProstateTesticular NeoplasmsEndometrial CarcinomaInterventionalhttps://newmdr.ecrin.org/Study/2036215United States2Cancer VaccineECRIN MDRCompletedfalseSafety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.2007-02-152036215NCT00423254